ENYO Pharma participera au 3\u00e8me symposium annuel Alport Research Hub organis\u00e9 par l’association Alport UK le 3 juillet 2026 \u00e0 London.<\/p>\n\n\n\n
ENYO Pharma rencontrera les patients et leur famille pour leur pr\u00e9senter les r\u00e9sultats de son \u00e9tude clinique de Phase 2 “ALPESTRIA-1” avec Vonafexor chez les patients atteints du syndrome d’Alport : “Vonafexor: Phase 2 Efficacy and Safety Results in Progressive Alport Syndrome.”<\/p>\n","protected":false},"excerpt":{"rendered":"
ENYO Pharma participera au 3\u00e8me symposium annuel Alport Research Hub organis\u00e9 par l’association Alport UK le 3 juillet 2026 \u00e0 London.<\/p>\n
ENYO Pharma rencontrera les patients et leur famille pour leur pr\u00e9senter les r\u00e9sultats de son \u00e9tude clinique de Phase 2 “ALPESTRIA-1” avec Vonafexor chez les patients atteints du syndrome d’Alport : “Vonafexor: Phase 2 Efficacy and Safety Results in Progressive Alport Syndrome.”<\/p>\n
Lire la suite »<\/a><\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[12],"tags":[],"class_list":["post-7354","post","type-post","status-publish","format-standard","hentry","category-events-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"adm-cdubreuil","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/adm-cdubreuil\/"},"rttpg_comment":0,"rttpg_category":"\u00c9v\u00e9nements<\/a>","rttpg_excerpt":"ENYO Pharma participera au 3\u00e8me symposium annuel Alport Research Hub organis\u00e9 par l’association Alport UK le 3 juillet 2026 \u00e0 London. ENYO Pharma rencontrera les patients et leur famille pour leur pr\u00e9senter les r\u00e9sultats de son \u00e9tude clinique de Phase 2 “ALPESTRIA-1” avec Vonafexor chez les patients atteints du syndrome d’Alport : “Vonafexor: Phase 2…","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/7354","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=7354"}],"version-history":[{"count":2,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/7354\/revisions"}],"predecessor-version":[{"id":7356,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/7354\/revisions\/7356"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=7354"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=7354"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=7354"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}